LiStarFish - ANTICORPI PRIMARI E SECONDARI - Prodotti per la ricerca medica

Categorie
Video
Focus On
Guida
Social Network
NEW! Farmaci biologici specifici e nuovi anticorpi secondari coniugati con ADC

Therapeutic Antibodies & Secondary Antibody-drug conjugated (ADCs)

 

Secondary Antibodies ADC conjugates   

new.pngmoradec_logo.gif

Secondary Antibody-drug Conjugates are great research tools for pre-screening your antibody leads as ADC candidates. They consist of a secondary antibody and a small amount of a highly potent cytotoxic drug, and a linker species that enables the attachment of the cytotoxin to the antibody.

We provide various Secondary ADC products which include:

  • Anti-Rat IgG (H+L) ADCs
  • Anti-Rat IgG (H+L) Fab ADCs
  • Anti-Rat IgG (Fc Specific) ADCs
  • Anti-Rat IgG (Fc Specific) Fab ADCs
  • Anti-Rabbit IgG (H+L) ADCs
  • Anti-Rabbit IgG (H+L) Fab ADCs
  • Anti-Rabbit IgG (Fc Specific) ADCs
  • Anti-Rabbit IgG (Fc Specific) Fab ADCs
  • Anti-Mouse IgG (Fc Specific) ADCs
  • Anti-Mouse IgG (Fc Specific) Fab ADCs
  • Anti-Human IgG (Fc Specific) ADCs
  • Anti-Human IgG (Fc Specific) Fab ADCs
  • Anti-Human IgG (Fab Specific) ADCs
 secondary_adc.png
Contattaci per ulteriori informazioni.
 
***************************************************************************************************

Therapeutic Antibodies

Therapeutic antibodies, which we know as antibodies, in response to foreign antigens (Ags) and prophesied their use as ‘magic bullets’ to specifically attack a wide variety of diseases including immune disorders, cancers, and infections. There are currently 65 monoclonal antibodies (mAbs) approved by FDA for clinical use and more than 350 are in clinical trials. Therapeutic antibodies currently enjoy unprecedented success, growth in research and revenues, and recognition of their potential.

Therapeutic Antibodies - Creative Biolabs

Advantages of Therapeutic antibodies:
• High-affinity
• High specificity and low off-target activity
• Low or non immunogenic
• Generally safe

We are the pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer an extensive range of therapeutic antibodies specifically attack a wide variety of diseases.
   
Products Database
  • Mouse monoclonal antibodies (60)
  • Rat monoclonal antibodies (2)
  • Chimeric monoclonal antibodies (33)
  • Humanized monoclonal antibodies (155)
  • Human monoclonal antibodies (112)
Dozens of therapeutic antibodies will soon be available, for details, feel free to Contact Us
Hot Products
Cat Product Name Abbr
CRE-TAB-008 Anti-Human C5 Therapeutic Antibody (Soliris) Eculizumab
CRE-TAB-236 Anti-Human CD38 Therapeutic Antibody Daratumumab
CRE-TAB-019 Anti-Human CD3 Therapeutic Antibody (Orthoclone OKT3) muromonab-CD3
CRE-TAB-067 Anti-Human CTLA4 Therapeutic Antibody (Yervoy) Ipilimumab
CRE-TAB-003 Anti-Human EGFR Therapeutic Antibody (Erbitux) Cetuximab
CRE-TAB-005 Anti-Human ErbB2 Therapeutic Antibody (Herceptin) Trastuzumab
CRE-TAB-004 Anti-Human CD25 Therapeutic Antibody (Simulect) Basiliximab
CRE-TAB-023 Anti-Human CD25 Therapeutic Antibody (Zenapax) Daclizumab
CRE-TAB-016 Anti-Human CD20 Therapeutic Antibody (MabThera) Rituximab
CRE-TAB-006 Anti-Human TNF Therapeutic Antibody (Remicade) Infliximab
CRE-TAB-010 Anti-Human TNF Therapeutic Antibody (Humira) Adalimumab
CRE-TAB-011 Anti-Human VEGF Therapeutic Antibody (Avastin) Bevacizumab
CRE-TAB-009 Anti-RSV Therapeutic Antibody (Synagis) Palivizumab
CRE-TAB-002 Anti-Human TAG72 Therapeutic Antibody (OncoScint CR103) Satumomab Pendetide
   
 **************************************************************************************************
   

Antibody-drug conjugates (ADCs) Products

Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of patients with cancers. Typically, an ADC is composed of three core elements: the monoclonal antibody, the linker and the cytotoxic agent. In developing ADCs, an anticancer drug is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). Antibodies track these proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer.Typical examples areBrentuximab vedotin (SGN35), Trastuzumab-emtansine (T-DM1), Inotuzumab ozogamicin (CMC-544) and Gemtuzumab ozogamicin.

Our scientists are focusingon applying excellent science and technology to discover and develop potential new ADCs with the goal of becoming first-in-class therapeutics. We also provide custom ADCsdesign and construction services. Besides expression and purification of ADCs, we also provided pharmacokinetics studies, HPLC/ELISA/TFC-MS/MS analysis for free drug and pharmacokinetics analysis.


ADC Name Cytotoxin Linker MAb Target
ABT-414-VC-MMAE Auristatin MMAE Valine–citrulline ABT-414 EGFR
AGS-16M8F-VC-MMAE Auristatin MMAF Valine–citrulline AGS-16M8F AGS-16
AMG-172-SMCC-DM1 Maytansine DM1 SMCC AMG-172 CD70 (CD27L)
AMG-595-SMCC-DM1 Maytansine DM1 SMCC AMG-595 EGFRviii
ARX788 Amberstatin (AS269) Valine–citrulline ARX788 HER2
ASG-15ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-15ME SLTRK6
ASG-22CE-VC-MMAE Auristatin MMAE Valine–citrulline ASG-22CE Nectin 4
ASG-22ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-22ME Nectin 4
ASG-5ME-VC-MMAE Auristatin MMAE Valine–citrulline ASG-5ME SLC44A4 (AGS-5)
BAY-79-4620-VC-MMAE Auristatin MMAE Valine–citrulline BAY-79-4620 CA-IX
BAY-94-9343-SPDB-DM4 Maytansine DM4 SPDB BAY-94-9343 Mesothelin
BIIB015-MCC-MMAE Auristatin MMAE MCC BIIB015 CFC1B (Cripto)
Brentuximab-VC-MMAE Auristatin MMAE Valine-citrulline Brentuximab vedotin (SGN35) CD30
BT-062-SPP-DM4 Maytansine DM4 SPP BT-062 CD138
Coltuximab-SPDB-DM4 Maytansine DM4 SPDB Coltuximab Ravtansine (SAR-3419) CD19
EC-mAb-Maleimidocaproyl Phenylalanine-PBD dimer Pyrrolobenzodiazepine (PBD) dimer Maleimidocaproyl Phenylalanine SGN- CD33A (EC-mAb) CD22
Epratuzumab–Lysine-SN38 Irinotecan metabolite (SN38) Lysine Epratuzumab–SN-38 CD33 and CD22
Gemtuzumab-Hydrazone-N-acetyl- γ Calicheamicin N-acetyl- γ Calicheamicin Hydrazone Gemtuzumab ozogamicin GPNMB (Glycoprotein NMB)
Glembatumumab-VC-MMAE Auristatin MMAE Valine–citrulline Glembatumumab vedotin (CDX-011) Tissue Factor (TF)
HuMax-TF-VC-MMAE Auristatin MMAE Valine–citrulline HuMax-TF-ADC CD37
IMGN-529-SPDB-DM4 Maytansine DM4 SPDB IMGN-529 Folate receptor 1
IMGN-853-Lysine-SN38 Irinotecan metabolite (SN38) Lysine IMGN-853 TACSTD2 / TROP2 or EGP1
IMMU-132-Hydrazone-Doxorubicin Doxorubicin Hydrazone IMMU-132 (hRS7-SN38) CD22
Inotuzumab-Hydrazone-N-acetyl- γ Calicheamicin N-acetyl- γ Calicheamicin Hydrazone (4-(4-acetylphenoxy)butanoic acid) Inotuzumab ozogamicin (CMC-544) CEA-CAM4/CD66e
Labetuzumab-Carbonate-SN38 Irinotecan metabolite (SN38) Carbonate Labetuzumab-SN-38 (IMMU-130) CD56
Lorvotuzumab-N-succinimidyl-4-(2-pyridyldithio)butyrate-DM1 Maytansine DM1 (N-succinimidyl-4-(2-pyridyldithio)butyrate) Lorvotuzumab mertansine (IMGN-901) CD70 (TNFSF7)
MDX-1203-Di-peptide-Duocarmycin Duocarmycin (DNA damage) Di-peptide MDX-1203 STEAP1
Milatuzumab doxorubicin (IMMU-110) Doxorubicin Hydrazone Milatuzumab doxorubicin (IMMU-110) Mucin 16
MLN-0264-VC-MMAE Auristatin MMAE Valine–citrulline MLN-0264 CD79b
PF-0626350-VC-MMAE Auristatin MMAE Valine–citrulline PF-0626350  
Pinatuzumab-VC-MMAE Auristatin MMAE Valine–citrulline Pinatuzumab vedotin (RG-7593 / DCDT 2980S) NaPi2b
PSMA-ADC-SPDB-DM4 Maytansine DM4 SPDB PSMA-ADC  
RG-7450-VC-MMAE Auristatin MMAE Valine–citrulline RG-7450 / DSTP 3086 S Endothelin receptor ETB
RG-7458-SMCC-DM1 Maytansine DM1 SMCC RG-7458 / DMUC 5754 A CA6
RG-7596-VC-MMAE Auristatin MMAE Valine–citrulline RG-7596 / DCDS4501A  
RG-7599-VC-MMAE Auristatin MMAE Valine–citrulline RG-7599 / DNIB 0600 A CD70
RG-7600-VC-MMAE Auristatin MMAE Valine–citrulline RG-7600 CD70
RG-7636-VC-MMAE Auristatin MMAE Valine–citrulline RG-7636 CD19
SAR-566658-SPDB-DM4 Maytansine DM4 SPDB SAR-566658 LIV1
SC16LD6.5-Di-peptide-DNA damaging agent DNA damaging agent Di-peptide SC16LD6.5 HER2
SGN-75-VC-MMAE Auristatin MMAF Valine–citrulline SGN-75 CD70
SGN-CD19A-VC-MMAE Auristatin MMAE Valine–citrulline SGN-CD19A  
SGN-LIV1-A-VC-MMAE Auristatin MMAE Valine–citrulline SGN-LIV1-A  
SGN-Maleimidocaproyl Phenylalanine-PBD dimer Pyrrolobenzodiazepine (PBD) dimer Maleimidocaproyl Phenylalanine SGN CD70 A  
Trastuzumab-SMCC-DM1 Maytansine DM1 SMCC Trastuzumab-emtansine (T-DM1)  
Vorsetuzumab-VC-MMAE Auristatin MMAF Valine–citrulline Vorsetuzumab mafodotin
 
 Per ulteriori informazioni contattaci.
design & hosting by Playground Web Agency Milano
0.06 seconds to elaborate this page.